Gate Neurosciences to Share New Data and Research Insights on its Synaptic Function Molecules with Multiple Posters at 2024 ASCP Annual Meeting
May 15 2024 - 2:41PM
Business Wire
- Two poster presentations will feature novel findings of
preclinical metaplasticity research and updated data from the
recent apimostinel Phase 1 qEEG biomarker study
- Company will host its 3rd annual R&D Day with investigators
and key opinion leaders to share new insights ahead of an upcoming
Phase 2 MDD study with zelquistinel
Gate Neurosciences, a clinical-stage biotechnology company using
precision medicine to develop next-generation neuroscience
therapies, today announced upcoming activities at the 2024 annual
meeting of the American Society of Clinical Psychopharmacology
(ASCP), being held in Miami Beach, FL, from May 28-31, 2024.
The company will present new preclinical and clinical data
supporting its NMDAR PAM portfolio and will share novel insights
from internal research on the biological mechanisms of
neuroplasticity and synaptic function.
Specifically, Gate Neurosciences will highlight its cutting-edge
research on how a single dose of neuroplasticity-enhancing drugs
can trigger both rapid-onset (i.e. hours) and long-lasting
therapeutic effects (i.e. weeks), a phenomenon termed ‘event-driven
pharmacology’. Gate’s new preclinical and clinical insights have
yielded critical findings on CNS-specific ‘event-driven
pharmacology’ and the importance of dosing intervals to optimize
plasticity treatments.
The company plans to share these new insights at its 3rd annual
R&D Day at the conference with leading members of the
scientific community in attendance. The session will also include
updates on an upcoming Phase 2 study with a once-weekly oral
program, zelquistinel (GATE-251), for Major Depressive
Disorder.
Gate Neurosciences 3rd Annual R&D
Day at ASCP 2024: Location: Loews Hotel Miami
Beach, Florida Date: Tuesday, May 28, 2024 Time:
12:15 p.m. to 1:45 p.m.
“Over the past few years, the Gate team has made considerable
progress in understanding mechanisms that rapidly and durably
enhance synaptic function for treating CNS diseases. Dosing these
compounds the right way is critical to success,” stated Mike
McCully, CEO of Gate Neurosciences. “We look forward to sharing our
new data and insights with the psychiatry community at the ASCP
conference and discussing updated plans for our Phase 2 study of
once-weekly oral zelquistinel in depression.”
Poster Presentation Details:
Poster #T14 Title: Apimostinel, a Novel NMDAR Modulator with
Rapid-Acting, Sustained Effects and Favorable Drug-Like properties:
Preclinical Studies Abstract Number: T14 Presentation
Session: Poster Session II, Salon 4 Presentation Date and
Time: 12:30pm – 2:25pm, Thursday May 30th 2024 Lead
Author: Jeffrey Burgdorf, PhD
Poster #T14 details new preclinical data supporting apimostinel
as an acute psychiatry drug candidate with lasting metaplasticity
effects. Key takeaways include:
- Single dose of apimostinel acutely enhanced LTP with
metaplasticity lasting 7 days, and produced robust
antidepressant-like effects without ketamine-like side effects
- Apimostinel dose-dependently enhanced qEEG alpha in correlation
with CSF exposure, as a biomarker of NMDA receptor target
activation
- Repeat doses of apimostinel led to larger and longer-lasting
metaplastic effects
At the Society of Biological Psychiatry (SOBP) Annual Meeting
earlier this month, Gate presented additional data on the specific
NMDAR PAM mechanism of action of apimostinel.
Poster #T21 Title: A Phase 1 Safety, Pharmacokinetics
(PK) and Quantitative Electroencephalography (qEEG)
Pharmacodynamics Study of Single and Multiple Ascending Doses of
Intravenous Apimostinel Compared with Placebo in Healthy Volunteers
Abstract Number: T21 Presentation Session: Poster
Session II, Salon 4 Presentation Date and Time: 12:30pm –
2:25pm, Thursday May 30th 2024 Lead Author: Ronald M. Burch,
MD PhD
Poster #T21 is the first scientific presentation of findings
from the apimostinel Phase 1 clinical trial assessing safety and
qEEG biomarkers. Key takeaways include:
- Apimostinel was generally safe and well-tolerated following
multiple doses from 1-25mg
- Apimostinel dose-dependently stimulated qEEG alpha power
- qEEG alpha power stimulation with apimostinel was consistent
with CSF Cmax drug concentrations that maximally stimulate NMDA
receptors in vitro
- qEEG alpha power stimulation with apimostinel was consistent
with efficacious doses in a previous Phase 2a clinical MDD
study
Full abstracts will be published by ASCP following the
conclusion of the 2024 Annual Meeting.
About Gate Neurosciences
Gate Neurosciences, headquartered in Indianapolis, is a
precision medicine biotechnology company focused on advancing
next-generation central nervous system (CNS) treatments that
address the growing needs in mental health. The company is
developing a portfolio of novel mechanisms of action that enhance
synaptic function to address neuropsychiatric and neurocognitive
diseases, including major depressive disorder. Using learnings from
extensive clinical, preclinical and translational data, along with
a better understanding of CNS development challenges, the company
is advancing its clinical pipeline using evidence-driven, precision
psychiatry approaches.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240515180606/en/
Media Contact: Azeem Zeekrya HDMZ azeem.zeekrya@hdmz.com
312-506-5244
Corporate Contact: Rob Houghtaling - Sr. Director,
Corporate Development Gate Neurosciences, Inc.
rob.houghtaling@gateneuro.com